Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:09:01 EDT Sun 05 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:MRKR from 2023-05-04 to 2024-05-03 - 25 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-04-08 07:01
U
U:MRKR
News Release
200
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
2024-03-26 12:44
U
U:MRKR
SEDAR Annual Report
803
SEDAR MD & A
2024-03-25 17:45
U
U:MRKR
News Release
200
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
2024-03-22 12:31
U
U:MRKR
News Release
200
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
2024-01-22 07:30
U
U:MRKR
News Release
200
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for ¢ € œNeldaleucel ¢ € as Nonproprietary Name for MT-601
2024-01-08 08:25
U
U:MRKR
News Release
200
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
2023-12-21 11:00
U
U:MRKR
News Release
200
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During ¢ € œJ.P. Morgan Week 2024 ¢ €
2023-12-11 07:00
U
U:MRKR
News Release
200
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
2023-11-09 20:40
U
U:MRKR
SEDAR Interim Financial Statements
812
SEDAR Interim Financial Statements
2023-11-09 20:35
U
U:MRKR
SEDAR Interim MD & A
813
SEDAR Interim MD & A
2023-11-09 17:00
U
U:MRKR
News Release
200
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
2023-09-11 07:00
U
U:MRKR
News Release
200
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
2023-08-30 08:01
U
U:MRKR
News Release
200
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-17 09:04
U
U:MRKR
News Release
200
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
2023-08-14 18:01
U
U:MRKR
SEDAR Interim Financial Statements
812
SEDAR Interim Financial Statements
2023-08-14 16:30
U
U:MRKR
News Release
200
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-07 07:00
U
U:MRKR
News Release
200
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
2023-07-26 07:00
U
U:MRKR
News Release
200
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
2023-07-10 07:00
U
U:MRKR
News Release
200
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
2023-06-26 07:00
U
U:MRKR
News Release
200
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
2023-06-12 07:01
U
U:MRKR
News Release
200
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
2023-05-31 06:30
U
U:MRKR
News Release
200
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
2023-05-16 12:16
U
U:MRKR
SEDAR MD & A
815
SEDAR MD & A
2023-05-16 12:11
U
U:MRKR
SEDAR Interim Financial Statements
812
SEDAR Interim Financial Statements
2023-05-08 07:30
U
U:MRKR
News Release
200
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer